LC-MS/TOF and UHPLC-MS/MS study of in vivo fate of rifamycin isonicotinyl hydrazone formed on oral co-administration of rifampicin and isoniazid

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 3, 2010, Pages 377-383

  Prasad, Bhagwat ^a   Singh, Saranjit ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Isoniazid; LC MS TOF; Rifampicin; Rifamycin isonicotinyl hydrazone; UHPLC MS MS

Indexed keywords

3 FORMYLRIFAMPICIN ISONICOTINYL HYDRAZONE; ISONIAZID; ISONIAZID DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CALIBRATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FECES LEVEL; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HYDRAZONES; ISONIAZID; MASS SPECTROMETRY; MOLECULAR STRUCTURE; QUALITY CONTROL; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 77649186648     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.07.014     Document Type: Article

References (28)

1. Bhutani H., Mariappan T.T., and Singh S. The physical and chemical stability of anti-tuberculosis fixed-dose combination products under accelerated climatic conditions. Int. J. Tuberc. Lung Dis. 8 (2004) 1073-1080
2. Bhutani H., Mariappan T.T., and Singh S. An explanation for the physical instability of a marketed fixed dose combination (FDC) formulation containing isoniazid and ethambutol and proposed solutions. Drug Dev. Ind. Pharm. 30 (2004) 667-672
3. H. Bhutani, Ph.D. Thesis. National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India, (2006) pp. 57-73.
4. Laserson K.F., Kenyon A.S., Kenyon T.A., Layloff T., and Binkin N.J. Substandard tuberculosis drugs on the global market and their simple detection. Int. J. Tuberc. Lung Dis. 5 (2001) 448-454
5. Sabri N.A., and El-Zorba H.Y. In vitro and in vivo effects of isoniazid on stability and pharmacokinetics of rifampicin. Egypt J. Pharm. Sci. 44 (2003) 19-38
6. Rookkapan K., Chongsuvivatwong V., Kasiwong S., Pariyawatee S., Kasetcharoen Y., and Pungrassami P. Deteriorated tuberculosis drugs and management system problems in lower southern Thailand. Int. J. Tuberc. Lung Dis. 9 (2005) 654-660
7. Acocella G. Human bioavailability studies. Bull. Int. Union Tuberc. Lung Dis. 64 (1989) 38-40
8. Bhutani H., Singh S., Jindal K.C., and Chakraborti A.K. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J. Pharm. Biomed. Anal. 39 (2005) 892-899
9. Kumar V., Prasad B., and Singh S. Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov. Today Ther. Strat. 5 (2008) 63-71
10. Pillai G., Fourie P.B., Padayatchi N., Onyebujoh P.C., McIlleron H., Smith P.J., and Gabriels G. Recent bioequivalence studies on fixed-dose combination antituberculosis drug fomulations available on the global market. Int. J. Tuberc. Lung Dis. 3 (1999) S309-S316
11. Shishoo C.J., Shah S.A., Rathod I.S., Salave S.S., and Vora M.J. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dosed combination (FDC) formulation. Int. J. Pharm. 228 (2001) 53-67
12. Singh S., Mariappan T.T., Sankar R., Sarda N., and Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int. J. Pharm. 228 (2001) 5-17
13. Singh S., and Mohan B. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products. Int. J. Tuberc. Lung Dis. 7 (2003) 298-303
14. Mariappan T.T., and Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int. J. Tuberc. Lung Dis. 7 (2003) 797-803
15. Mariappan T.T., Jindal K.C., and Singh S. Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone. J. Pharm. Biomed. Anal. 36 (2004) 905-908
16. Singh S., Mariappan T.T., Sarda N., Kumar S., and Chakraborti A.K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 6 (2000) 405-410
17. Jindal K.C., Chaudhary R.S., Singla A.K., Gangwal S.S., and Khanna S. Dissolution test method for rifampicin-isoniazid fixed dose formulations. J. Pharm. Biomed. Anal. 12 (1994) 493-497
18. Seifart H.I., Parkin D.P., and Donald P.R. Stability of rifampin, isoniazid and pyrazinamide in suspensions used for the treatment of tuberculosis in children. Pediatr. Infect. Dis. 10 (1991) 827-831
19. Shishoo C.J., Shah S.A., Rathod I.S., Savale S.S., Kotecha J.S., and Shah P.B. Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm. 190 (1999) 109-123
20. http://www.who.int/phint/en/p/docf/ (accessed on: 20.04.09).
21. T.T. Mariappan, Ph.D. Thesis. National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India, (2004) pp. 127-146.
22. Russell D.W. Low circulating levels of acid-labile hydrazones after oral administration of isonicotinic acid hydrazide. Clin. Chim. Acta 41 (1972) 163-168
23. Timbrell J.A., and Wright J.M. Studies on the effects of isoniazid on acetylhydrazine metabolism in vivo and in vitro. Drug Metab. Dispos. 7 (1979) 237-240
24. Wright J.M., and Timbrell J.A. Factors affecting the metabolism of [14C]acetylhydrazine in rats. Drug Metab. Dispos. 6 (1978) 561-566
25. Peters J.H., Gill M., and Hayes V.E. The influence of d-glucose and p-aminosalicylic acid on the metabolism of isoniazid. Arch. Int. Pharmacodyn. Ther. 159 (1966) 340-352
26. Ellard G.A., Gammon P.T., and Wallace S.M. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine. Biochem. J. 126 (1972) 449-458
27. Kovarikova P., Mrkvickova Z., and Klimes J. Investigation of the stability of aromatic hydrazones in plasma and related biological material. J. Pharm. Biomed. Anal. 47 (2008) 360-370
28. Anonymous. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD, 2001.